These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37353450)

  • 1. Vaccination with HepB-CpG vaccine in individuals undergoing immune suppressive drug therapy.
    Perrillo R; Garrido LF; Ma TW; Rahimi R; Lilly B
    Vaccine; 2023 Jul; 41(31):4457-4461. PubMed ID: 37353450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antibody persistence following booster vaccination with three doses of hepatitis B vaccines among low-response adults in Zhangqiu county of Shandong province: 24-month of follow-up from 2009].
    Yan B; Lyu J; Liu J; Feng Y; Xu A; Chen S; Zhou L; Liang X; Cui F; Wang F; Zhang L
    Zhonghua Yu Fang Yi Xue Za Zhi; 2014 Dec; 48(12):1043-7. PubMed ID: 25619213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune persistence 17 to 20 years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination.
    Zhao YL; Han BH; Zhang XJ; Pan LL; Zhou HS; Gao Z; Hao ZY; Wu ZW; Ma TL; Wang F; Li Q; Bi SL; Ma JC
    BMC Infect Dis; 2019 May; 19(1):482. PubMed ID: 31146699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease.
    Girndt M; Houser P; Manllo-Karim R; Ervin JE; Charytan C; Chow S; Symonian-Silver M; Lehrner L; Linfert D; Shemin D; Michelsen A; Xie F; Janssen RS
    Vaccine; 2023 May; 41(20):3224-3232. PubMed ID: 37085451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of booster dose vaccination 21- to 32-years after primary vaccination with hepatitis B vaccine in the population born from 1986 to 1996 in Zhengding County of Hebei Province].
    Zhang XJ; Wu ZW; Zhang YH; Li MJ; Zhou HS; Han BH; Hao ZY; Chu J; Gao Z; Ma JC; Zhao YL
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Sep; 54(9):942-946. PubMed ID: 32907282
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study.
    Girndt M; Plüer M; Dellanna F; Michelsen AK; Beige J; Toussaint K; Wehweck HJ; Koch M; Hafezi Rachti S; Faust J; Bosselmann HP; Witzke O; Janssen RS;
    Hum Vaccin Immunother; 2022 Nov; 18(6):2136912. PubMed ID: 36269938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune response to different types of hepatitis B vaccine booster doses 2-32 years after the primary immunization schedule and its influencing factors.
    Zhao YL; Pan LL; Hao ZY; Jin F; Zhang YH; Li MJ; Zhang XJ; Han BH; Zhou HS; Ma TL; Wang F; Ma JC; Shen LP; Li Q
    Int J Infect Dis; 2020 Apr; 93():62-67. PubMed ID: 32004687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody response to revaccination among adult non-responders to primary Hepatitis B vaccination in China.
    Zhang L; Liu J; Lu J; Yan B; Song L; Li L; Cui F; Zhang G; Wang F; Liang X; Xu A
    Hum Vaccin Immunother; 2015; 11(11):2716-22. PubMed ID: 26252481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effectiveness of rapid hepatitis B vaccination with different vaccine dosages and types in adults].
    Nie L; Pang XH; Zhang Z; Ma JX; Liu XY; Qiu Q; Liang Y; Li Q; Zhang W
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Sep; 38(9):1151-1155. PubMed ID: 28910921
    [No Abstract]   [Full Text] [Related]  

  • 10. A real world comparison of HepB (Engerix-B®) and HepB-CpG (Heplisav-B®) vaccine seroprotection in patients receiving maintenance dialysis.
    Manley HJ; Aweh G; Frament J; Ladik V; Lacson EK
    Nephrol Dial Transplant; 2023 Feb; 38(2):447-454. PubMed ID: 35150277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Matching study on immune response between single anti-HBc positivity and healthy adults after primary immunization and revaccination of hepatitis B vaccine].
    Liu J; Lyu J; Yan B; Feng Y; Zhang L; Xu A
    Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Oct; 35(10):1091-4. PubMed ID: 25567010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-HBs persistence following revaccination with three doses of hepatitis B vaccine among low-responsive adults after primary vaccination: a 4-year follow-up study].
    Lyu JJ; Yin XW; Yan BY; Liu JY; Feng Y; Wu WL; Chen SY; Zhou LB; Liang XF; Cui FQ; Wang FZ; Zhang L; Xu AQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Jun; 50(6):491-6. PubMed ID: 27256727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) in adults receiving hemodialysis.
    Awad AM; Ntoso A; Connaire JJ; Hernandez GT; Dhillon K; Rich L; Henderson H; Lynn R; Hyer RN; Xie F; Erby K; Janssen RS;
    Vaccine; 2021 Jun; 39(25):3346-3352. PubMed ID: 34001345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-HBs persistence after revaccination with three doses of hepatitis B vaccine among non-responsive adults: a 4-year of follow-up study].
    Zhang L; Yan BY; Lyu JJ; Liu JY; Feng Y; Wu WL; Cao CZ; Chen SY; Zhou LB; Liang XF; Cui FQ; Wang FZ; Zhang GM; Xu AQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Jun; 50(6):497-502. PubMed ID: 27256728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effect of vaccinating infants with a 5 µg recombinant yeast-derived hepatitis B vaccine and the need for a booster dose in China.
    Miao N; Zheng H; Sun X; Zhang G; Wang F
    Sci Rep; 2020 Oct; 10(1):18155. PubMed ID: 33097788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of antibody persistence after primary immunization with 5 μg and 10 μg recombinant hepatitis B vaccine among newborns with normal and high response: a five-year following-up].
    Zhang L; Zhang W; Lyu JJ; Zhang JJ; Liu JY; Yan BY; Feng Y; Liang XF; Cui FQ; Wang FZ; Zhang GM; Xu AQ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Sep; 38(9):1156-1160. PubMed ID: 28910922
    [No Abstract]   [Full Text] [Related]  

  • 17. [Anti-HBs persistence following primary vaccination with three doses of hepatitis B vaccine among normal and high-responder adults: a 3-year follow-up study].
    Lyu JJ; Zhang L; Yan BY; Liu JY; Feng Y; Song LZ; Chen SY; Zhou LB; Liang XF; Cui FQ; Wang FZ; Xu AQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Jun; 50(6):478-83. PubMed ID: 27256725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-HBs persistence after revaccination with three doses of hepatitis B vaccines among non-responsive adults: 24-month of follow-up].
    Zhang L; Lyu J; Yan B; Liu J; Feng Y; Chen S; Zhou L; Liang X; Cui F; Wang F; Xu A
    Zhonghua Yu Fang Yi Xue Za Zhi; 2015 Sep; 49(9):782-7. PubMed ID: 26733135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antibody persistence following primary vaccination with hepatitis B vaccine among normal and high-responder adults: a 5-year follow-up study].
    Wu WL; Yan BY; Lyu JJ; Liu JY; Feng Y; Chen SY; Zhou LB; Liang XF; Cui FQ; Wang FZ; Zhang GM; Zhang L; Xu AQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Jun; 50(6):484-90. PubMed ID: 27256726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A booster hepatitis B vaccine for children with maternal HBsAg positivity before 2 years of age could effectively prevent vaccine breakthrough infections.
    Song Y; Zhang X; Liu M; Zhai X; Liu J; Li Y; Li L; Xiao Y; Duan Z; Jiang J; Ding F; Zhu L; Jiang J; Zou H; Zhuang H; Wang J; Li J
    BMC Infect Dis; 2022 Nov; 22(1):863. PubMed ID: 36401190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.